The Oncology Institute, Inc. shares fall 1.18% intraday as IDEAYA Biosciences announces positive trial data for darovasertib and crizotinib combination.

martes, 2 de septiembre de 2025, 9:59 am ET1 min de lectura
TOI--
The Oncology Institute, Inc. declined 1.18% in intraday trading. The recent news events do not directly relate to The Oncology Institute, Inc. and therefore do not provide a clear cause for the stock's decline.

The Oncology Institute, Inc. shares fall 1.18% intraday as IDEAYA Biosciences announces positive trial data for darovasertib and crizotinib combination.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios